ReviewThe Journal of infectious diseases2017
Developing a Public Health Response to Mycoplasma genitalium.
Review in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence ofSexually transmitted infections · 2018Pooled it
- Isolation, prevalence, and antimicrobial resistance profiles of Ureaplasma spp. and Mycoplasma hominis in cervical secretions from pregnant and postpartum women in Hangzhou, China.BMC pregnancy and childbirth · 2026Article
- Treatment Approaches for RefractoryOpen forum infectious diseases · 2026Article
- Mathematical analysis of Mycoplasma Genitalium transmission dynamics: A compartmental model with nonlinear interactions and treatment effects.PLOS global public health · 2026Article
- Exploring psychosocial factors influencing sexually transmitted infection intention testing among medical students: a cross-sectional study in two universities.Frontiers in public health · 2024Observational
- Latest Advances in Laboratory Detection of Mycoplasma genitalium.Journal of clinical microbiology · 2023Review
- Evaluation of molecular testing for Mycoplasma genitalium for symptomatic women.Irish journal of medical science · 2022Article
- Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches.Emerging infectious diseases · 2022Article
- Article
- Prevalence ofJournal of medical microbiology · 2021Article
- High prevalence of circulating dual-class resistantJAC-antimicrobial resistance · 2021Article
- Mycoplasma genitalium and Other Reproductive Tract Infections in Pregnant Women, Papua New Guinea, 2015-2017.Emerging infectious diseases · 2021Article
- Brazilian Protocol for Sexually Transmitted infections, 2020: pelvic inflammatory disease.Revista da Sociedade Brasileira de Medicina Tropical · 2021Article
- Macrolide and fluoroquinolone associated mutations in Mycoplasma genitalium in a retrospective study of male and female patients seeking care at a STI Clinic in Guangzhou, China, 2016-2018.BMC infectious diseases · 2020Article
- Mycoplasma genitalium Detection in Urogenital Specimens from Symptomatic and Asymptomatic Men and Women by Use of the cobas TV/MG Test.Journal of clinical microbiology · 2020Article
- Anorectal and Urogenital Mycoplasma genitalium in Nigerian Men Who Have Sex With Men and Transgender Women: Prevalence, Incidence, and Association With HIV.Sexually transmitted diseases · 2020Article
- Mycoplasma genitalium Antimicrobial Resistance in Community and Sexual Health Clinic Patients, Auckland, New Zealand.Emerging infectious diseases · 2020Article
- Article
- Article
- Anti-Mycoplasma Activity of Daptomycin and Its Use for Mycoplasma Elimination in Cell Cultures of Rickettsiae.Antibiotics (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Although Mycoplasma genitalium is increasingly recognized as a sexually transmitted pathogen, at present there is no defined public health response to this relatively newly identified sexually transmitted infection. Currently available data are insufficient to justify routinely screening any defined population for M. genitalium infection. More effective therapies, data on acceptability of screening and its impact on clinical outcomes, and better information on the natural history of infection will likely be required before the value of potential screening programs can be adequately assessed. Insofar as diagnostic tests are available or become available in the near future, clinicians and public health agencies should consider integrating M. genitalium testing into the management of persons with sexually transmitted infection (STI) syndromes associated with the infection (ie urethritis, cervicitis, and pelvic inflammatory disease) and their sex partners. Antimicrobial-resistant M. genitalium is a significant problem and may require clinicians and public health authorities to reconsider the management of STI syndromes in an effort to prevent the emergence of ever more resistant M. genitalium infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.